Advances

FDA Approves Drug for Treatment of Nocturnal PolyuriaNoctiva is the first agent approved to temporarily decrease urine production in adults with nocturia from various causes.
Brodalumab approved for psoriasisDr. Mark Lebwohl talks about the FDA’s approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.
Once-daily diabetes drug approvedFDA approved 10 mg dapagliflozin and 5 mg saxagliptin (Qtern, AstraZeneca), to treat type 2 diabetes.
Center’s goal: Give skin disease researchers all they needA new research center makes a database of five million human pathology specimens and 22,000 living consented patients, all searchable by diagnoses, as well as cutting edge human analytic techniques available to anyone interested in carrying out translational skin disease research on human cells and tissues.
Literature updates in pediatric dermatologyA recent pediatric allergy study spells out how to safely introduce peanuts to high-risk (and other) children. Another study suggests that melatonin may have immunomodulatory effects in AD.

Poll

View Results